In bladder cancer (BC), MYC serves as a novel substrate of SETD8 to be methylated at lysine 412, which enhances MYC protein stability by preventing the CHIP‐mediated degradation and ultimately promotes tumor growth. This evidence concerns the gene KMT5A and urinary bladder cancer.